Integra LifeSciences has long been a leader in medical technology. In the early 1990s the company received the first-ever approval from the FDA of a regenerative device, the Integra Dermal Regeneration Template, also referred to as “artificial skin”. Integra has remained at the forefront of acellular tissue regeneration, with devices including Dura Mater and peripheral nerve. Using examples drawn from these devices, Dr. Twardowski will discuss the valuable but complex role of research in a regulated, industrial biomedical engineering company.

Thomas Twardowski, Ph.D., has been working in tissue regenerative materials since 1993 in both the industrial and academic sectors. He has co-authored papers that have appeared Journal of Biological Chemistry and Current Pharmaceutical Design. Sponsors for his biomaterials research have included the US Army, NIH and the Pennsylvania Keystone Innovation program. Dr. Twardowski has diverse research experience in biomaterials, composites and adhesives. He currently manages the core materials analysis laboratory for Integra Life Sciences Corporation.

Wednesday, October 5
1034 Emerging Technologies Building
9:10 a.m.